Podcasts about halve

In aflevering 87 praten we je weer even bij over de afgelopen week. Wat hebben we gedaan, en is Robbie klaar voor de halve marathon van Antwerpen op de 20ste september...Martin ging na 4 maanden weer eens naar buiten voor een simpele 5 km. We hebben de kalender, unieke runs, en bespreken het verschil tussen rennen op een loopband en in de buitenlucht. Een soort van update voor sporten in het najaar. Veel luisterplezier.

Het is AMBTS niet gelukt om via de rechter af te dwingen dat het bedrijf alsnog naar de beurs kan. Het College van Beroep voor het bedrijfsleven oordeelde dat de AFM het prospectus voor een beursgang van AMBTS, een spinoff van Amdax, terecht heeft geweigerd. Co-host Mauro Halve was tot begin dit jaar head of compliance bij Amdax, maar had geen enkele betrokkenheid bij AMBTS en ook geen financieel belang. De kern van de zaak was een etiket. De AFM stelde in de eerste ronde maar een vraag: bent u eigenlijk een beleggingsinstelling onder de richtlijn voor alternatieve beleggingsfondsen? Dat maakt veel uit, want voor een beleggingsinstelling gelden een vergunningsplicht en een onafhankelijke bewaarder. AMBTS hield vol een operationeel bedrijf te zijn dat bitcoin als werkkapitaal nodig heeft. Daar is anderhalf jaar over gesteggeld, met zeven versies van het prospectus. De rechter liep vijf voorwaarden langs en kwam uit bij een vraag: onderneem je, of beleg je voor anderen? Minstens zo belangrijk was wat daaraan voorafging. AMBTS vond dat alleen de zevende versie telde, maar het college oordeelde dat alles wat het bedrijf eerder had gezegd en gepubliceerd meeweegt, juist omdat er nog geen track record is. Wat volgens Halve het zwaarst woog, is niet eens het doel om 210.000 bitcoin te verzamelen, maar hoe het bedrijf zichzelf afrekende: op het aantal bitcoin per aandeel, en niet op omzet of winst. Hoger beroep is er niet, want dit is de hoogste rechter in dit soort zaken. Halve ziet nog drie routes: alsnog naar de beurs als beursfonds, eerst ondernemen en een track record opbouwen, of een nieuw prospectus. Die laatste route is smaller geworden. In Europa mochten Capital B, Bitcoin Group en H100 wel naar de beurs, en een beroep op gelijke behandeling werd afgewezen omdat toezichthouders zich daar nog niet nadrukkelijk hadden uitgesproken. Nu ligt er wel een route, en andere landen kunnen deze redenering volgen. In de marktanalyse legt Tim Stolte uit waarom de koers rond de 77.000 dollar blijft hangen na een stijging van ruim dertig procent vanaf de bodem. Beleggers heroverwegen hun posities, het momentum in altcoins is weg, en iedereen zit op de handen voor het rentebesluit van de Federal Reserve. Het is nagenoeg zeker dat de Fed voor het eerst in drie jaar verhoogt. Ondertussen probeerde minister van Financien Scott Bessent de lange rente te drukken met een terugkoopprogramma voor staatsobligaties, wat niet lukte: de dertigjaarsrente staat op het hoogste punt sinds 2004. Dat leverde een zwakkere dollar op, en daar profiteerden bitcoin en goud van. Tot slot de naamsverandering. De Verenigde Bitcoinbedrijven Nederland gaat verder als Nederlandse Vereniging Cryptodienstverleners. Volgens Halve verdwijnt bitcoin niet naar de achtergrond, maar sluit de naam beter aan bij wat de leden al langer doen. Co-host is Mauro Halve. Over de podcast Cryptocurrency are here to stay. In deze wekelijkse podcast gidst Daniël Mol je door het belangrijkste cryptonieuws, langs hypes en trends, voor- en tegenstanders en winst en verlies. In het A-deel bespreken we het laatste nieuws en in het B-deel gaan we in gesprek met een gast. Van cypherpunkpioneers tot grootbanken die aan de haal gaan met stablecoins, van Bitcoin tot Ethereum tot CBDC's. Alles passeert de revue.Reageren? Stuur dan een mail naar cryptocast@bnr.nl Gasten Mauro Halve is voorzitter van de Nederlandse Vereniging Cryptodienstverleners (NVC). Tim Stolte is portfolio manager van Amdax en analist bij Een Nieuwe Koers. Links Het College van Beroep over het prospectus van AMBTS De volledige uitspraak in de zaak AMBTS tegen de AFM VBNL gaat verder als Nederlandse Vereniging Cryptodienstverleners Host Daniël Mol is presentator en redacteur van de Cryptocast. Hij is sinds 2017 met Bitcoin bezig en kwam in 2021 bij het team van de Cryptocast. Redactie Daniël Mol Matthijs Damsteeg See omnystudio.com/listener for privacy information.

Danielle (40) kreeg een agressieve vorm van borstkanker toen ze 35 was. Ze onderging een dubbele borstamputatie en moest leren leven met een lichaam dat er ineens heel anders uitziet.Dit jaar liep ze de halve marathon. Zonder shirt, met haar littekens zichtbaar. Ze heeft geen borsten meer en ze weigert zich daarvoor te verstoppen.In deze aflevering vertelt Danielle openhartig over haar strijd tegen kanker, de impact van een dubbele borstamputatie, haar veranderde lichaamsbeeld en de krachtige keuze om tijdens de halve marathon zonder shirt hard te lopen.Instagram Danielle: https://www.instagram.com/kankerfit_journey?stkn=YmdoZDV6YTU2bWox

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Brought to you by the English Programme. Featuring news, politics, popular culture, celebrity trivia, quizzes, book readings, and a whole host of fun.Support Our Rescue Cats | Our Blog | Get New Episodes By Email | Rumble | X | YouTube | NewsK365 on Spreaker | Get New Blog Posts By Email | Throne Wishlist |

Er glasset halvt fyldt eller halvt tomt i FC Midtjylland efter 1-1 i Søhøjlandet, hvor ulvene burde have vundet i undertal? Det spørger vi panelet om i denne udsendelse. Vi taler om Silkeborgkampen, lidt om dommerne og VAR, om forventningerne til Conference League og sidst men ikke mindst kommer vi også ind på transfervinduet, som lukkes på onsdag. Jeres vært er Jakob Nørgaard Panelet består af Anders Susgaard, Dann Hvam og Nicolaj Bruun Rasmussen,

Zaterdag 8 augustus wordt Ype 50 (!) jaar. Om dat te vieren zijn in deze aflevering zijn liefste vrienden (dan wel exen) en zus Madeleen te gast, om een beeld te schetsen van een halve eeuw Ype. Een gezellige, rommelige, maar vooral feestelijke aflevering, die wordt afgesloten met een heuse aubade van Botte! Word Vriend van de Show! affiliatielink om Podimo 30 dagen gratis te proberen Adverteren in de Eeuw van de Amateur? Mail naar adverteren@dagennacht.nl!See omnystudio.com/listener for privacy information.

In today's MadTech Daily, we cover a new study finding AI is accelerating the collapse of Google Search referral traffic, the EU fining AliExpress €550m over failures to police illegal and counterfeit products, and Beehiiv launching Community and AI Copilot as it expands beyond newsletters.

In deze extra lange zomeraflevering praten we over de trainingen van Robbie op weg naar de halve van Antwerpen, loopjes tijdens zijn vakantie o.a in Zwitserland en Italie en kletsen we over onze fietsescapades van de laatste weken inclusief een audioslipje van een tochtje door de Beemster. Verder de snackattack, de kalender, espressoindex, unieke run en de mooiste fietsroutes van Nederland. Veel luisterplezier.Info: muziek leader: Remco Borsato, Mellowtones, stemmen Romy Snoeijers en Tess Stoker. Links: Pacing The Pacific https://youtu.be/IeGFmm4Krho?si=cwVIngMj6wx_AoRUBecky Bates: https://youtu.be/o-H1quL2_IM?si=hhnINqmd3QKP7jWiKijk ook op onze website, voor gasten, vers van de route, meer over ons, reizen en meer. www.opjeeigentempo.nl

Impressing friends with one's cooking skills is truly one of life's joys. Yumi has found a new way that is super easy and you probably have 90% of the ingredients already.BELINDA JEFFEREY's CHEESE BISCUITSCombine all the dry ingredients: 300g plain flour, 50g Self-raising flour and a teaspoon of salt. Add in 2tsp mild chilli flakes.Mix well in the food processor.Add 40g freshly grated parmesan and a whole grated block of Mersey Valley (250g).Add 250g cold, cubed butter, whizz the mixture. It will look crumbly and quite dry. While it's whizzing, add in the juice of 1 lemon. It will come together.Halve the dough. Fashion each half into logs about the width (girth?) of a 50c piece. Wrap in baking paper and chill until needed.When you're ready to cook them, pre-heat to oven to 180C. Slice 4-5mm pieces off the log and spread them out on a baking tray. Top with sesame seeds or nigella seeds and bake for about 14 minutes. Serve with beverages and olives!PRE-ORDER WELCOME TO FRIENDSHIP HERE.UPLOAD YOUR PROOF OF PURCHASE HERE for free friendship badges!Bored? Please fill in our survey HERE. Hosted on Acast. See acast.com/privacy for more information.

Stukje voor stukje kruipt het WK Voetbal richting het eind. Dinsdagavond was het Spanje dat zich wist te ontdoen van Frankrijk, vanavond zijn het Engeland en Argentinië die strijden voor de laatste finaleplaats. Het affiche van gisteren was vooraf duidelijk; de meest grandioze aanvalslinie tegenover de beste verdediging van het toernooi. Het bleek de Spaanse verdediging te zijn die de overhand had en het Franse sterrenensemble tandeloos maakte. Wie gaat zondag de tegenstander van Spanje zijn? Engeland heeft in onderlinge duels de overhand op de Argentijnen, maar werden in de geschiedenis wel twee keer op pijnlijke wijze door ze uitgeschakeld op een WK. We spraken erover met Engeland en Argentinië-kenner Joris van de Wier van Staantribune. Presentatie: Robert Denneman

De halve finale tussen Argentinië en Engeland op het WK zorgt ervoor dat ál het oud zeer tussen de landen weer wordt opgerakeld in de media. Van de Hand van God van Maradona tot aan de rode kaart van Beckham en zelfs de Falklandoorlog wordt door sommige media opgehaald om het vuurtje op te stoken. "Beide teams doen dit ook om ze zo scherp mogelijk te maken voor vanavond", stelt Xander van der Wulp, hoofdredacteur van NOS Sport. De WK-finale is ook in zicht, en dat belooft een groot spektakel te worden. Zo zal president Trump een rol spelen en staat er een heel leger aan artiesten klaar voor een pre-show en een soort Half Time Show zoals we gewend zijn van de Super Bowl. "Los van dat je je kunt afvragen hoe wenselijk het is om een traditie van de Super Bowl te transplanteren naar een andere sport, is het de vraag hoe goed het is dat de FIFA dit doet", vindt journalist Tahrim Ramdjan. "Het wordt interessant, sport en politiek komen vaak bij elkaar", aldus Van der Wulp.  Aan tafel zitten Xander van der Wulp, Tahrim Ramdjan en Spraakmaker Koen Aartsma. 

Welkom bij aflevering drieëndertig van FC Afkicken Komt Z’n Nest Uit! De ochtendshow waarin Lars van Velsum, Mart ten Have en Sieb Uenk je in dertig minuten bijpraten over het laatste WK-nieuws! Vanavond staat de eerste halve finale tussen Frankrijk en Spanje op het programma! We blikken hier, samen met NOS-commentator Anne de Jong, op vooruit! Verder bespreken we het onthaal van de Noorse selectie in Oslo, het souvenir van Haaland en de plannen van Infantino. We hebben weer een actuele quiz en er wordt weer voorspeld. Speel mee in de YouTube-comments en win die prachtige Brian Rompoe-sjaal! Namens Lars, Mart en Sieb: Veel luisterplezier! (00:00) Intro (06:30) Quiz (07:53) Bellen met Anne de Jong/Frankrijk - Spanje (17:28) Rondje om de wereld (24:04) Airbnb (25:31) Voorspellingen Matt Sleeps Het Matt Original matras is voor de 13e keer op rij uitgeroepen tot Beste uit de Test door de Consumentenbond en mag zich daarmee het beste matras van Nederland noemen! Ga naar mattsleeps.com/fcafkicken en krijg daar met de code FCA extra korting boven op de lopende acties. Ga op reis met Airbnb: https://www.airbnb.nl/ De nieuwste aflevering van The Skybox vind je hier: https://www.youtube.com/watch?v=a5uMdU9nhvk John Lion - Alleen in Dallas: https://www.youtube.com/watch?v=pEBVxIyN_1g See omnystudio.com/listener for privacy information.

De halve finales van het WK voetbal zijn aangebroken, met Frankrijk en Spanje die een van de grootste rivaliteiten in het internationale voetbal nieuw leven inblazen. Dit is het overzicht van dag 33 van het FIFA Wereldkampioenschap 2026 met een vooruitblik op de eerste halve finale en het laatste nieuws vanuit beide kampen.SBS Dutch, iedere woensdag en zaterdag om 11AM op SBS2. Meer op onze website of abonneer je op onze feed in Spotify of Apple Podcast.

In de nieuwste aflevering van WK Praat bespreken Wouter Bouwman, Kenneth Perez, Kees Kwakman en Karim El Ahmadi het laatste voetbalnieuws. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Aflevering 212 – Met Dat Team De PodcastHet WK 2026 nadert zijn ontknoping en de halve finalisten zijn bekend! In aflevering 212 blikken we uitgebreid terug op de kwartfinales, waarin Frankrijk met 2-0 te sterk was voor Marokko en Spanje na een spannende wedstrijd met 2-1 afrekende met België.Ook Engeland en Argentinië bereikten de laatste vier pas na verlenging. Engeland versloeg het verrassende Noorwegen met 2-1, terwijl regerend wereldkampioen Argentinië uiteindelijk met 3-1 won van Zwitserland. Bij beide wedstrijden vielen echter discutabele arbitrale beslissingen die in het voordeel van Engeland en Argentinië uitpakten. Hoe bepalend waren deze momenten en waren de uitslagen uiteindelijk terecht?Nu nog vier landen over zijn, kijken we vooruit naar twee absolute topaffiches. Kan Frankrijk opnieuw de finale bereiken of zet Spanje de volgende stap richting een nieuwe wereldtitel? En aan de andere kant van het schema: houdt de ervaring van Messi en Argentinië stand tegen Engeland, of schrijven de Engelsen eindelijk weer geschiedenis?Uiteraard geven wij ook onze voorspellingen. Wie heeft volgens ons de beste papieren om zich tot wereldkampioen te kronen? Welk land strandt vlak voor de eindstreep? En welke spelers kunnen in deze beslissende fase hét verschil maken?Dat en nog veel meer hoor je in aflevering 212 van Met Dat Team De Podcast!

Oranje is door Marokko uitgeschakeld op het WK. In de strafschoppenserie ging het mis voor het Nederlands elftal. De toekomst van bondscoach Ronald Koeman is na de uitschakeling logischerwijs onderwerp van gesprek. Het komt uitgebreid aan bod in VI ZSM met Simon Zwartkruis en Matthijs Vegter.See omnystudio.com/listener for privacy information.

De groepsfase zit er op! En dus zijn er 72 wedstrijden gespeeld. We maken de balans op en blikken verder vooruit op de wedstrijd van het Nederlands elftal, in Monterrey tegen Marokko. Vanuit een lobby in Houston praten Thierry Boon en Jeroen Stekelenburg over dag 17 van het WK. 

Når regnbueflaggene heises, blomstrer også pride-debatten. Hvordan påvirker skepsisen og en mer polarisert debatt det skeive livet i dag? Og er det egentlig noe lettere nå, enn før? Med forfatter og litteraturviter Pia Edvardsen. Foto: Olav Olsen, Aftenposten

A daily low dose of aspirin could significantly reduce the risk of bowel cancer in people with Lynch syndrome, an inherited condition that increases the likelihood of developing certain cancers.   In this episode, we explore the findings from the landmark CaPP3 trial, hear from a participant living with Lynch syndrome, and discuss how genomics could help shift healthcare from treatment to prevention.  Our host, Sharon Jones is joined by:  Dr Katie Snape, Principal Clinician for Population Health at Genomics England  Professor Sir John Burn, Professor of Clinical Genetics at Newcastle University  Drew Hyde, participant in the Cancer Prevention Programme (CaPP3)  Links:  Listen to: How can genomics help us understand cancer?  "I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think."  You can download the transcript or read it below. [00:00:00] Sharon: Welcome to Behind the Genes. In today's episode, we'll explore the research which shows how a low dose of aspirin can halve the risk of bowel cancer in people with Lynch syndrome. We'll hear about the real-life impact of living with the condition, and look at how genomics can help shape a more preventative approach to care in the future. [00:00:20] I'm Sharon Jones, and to help us unpack all of that, I'm joined by our guests, Dr. Katie Snape, principal clinician for population health at Genomics England; Sir John Burn, professor of clinical genetics at Newcastle University; and Drew Hyde, a participant in the Cancer Prevention Programme, which is also known as the CaPP3 trial. [00:00:42] So to start with the basics, Katie, can you walk us through what cancer is in simple terms? [00:00:50] Katie: Sure, Sharon. So, our body is made up of cells. Those are the building blocks that, that make us as humans and other creatures and plants. And our cells need to keep dividing throughout our lifetime as our bodies are growing and working normally. [00:01:06] And so we need to have processes in place in our body where our cells can divide, but then also stop dividing when we don't need them to carry on dividing. What happens in a cancer cell is basically that cell becomes abnormal, and it doesn't follow the normal checks and balances and rules of cell division. [00:01:23] So it starts to divide and grow uncontrollably, and it can start to invade other tissues and obviously, that can cause serious consequences. [00:01:33] Sharon: We'll hear a lot more from Dr. Katie Snape in this episode. But before we move on, I just wanted to flag that there was an episode of our Genomics 101 explainer series with Katie dedicated to helping us get to grips with how genomics can help us understand and diagnose cancer. [00:01:47] Do go and check that out. We'll put a link to that in the episode description. [00:01:54] So the World Health Organization estimates between 30 to 50% of all cancers are preventable. So, Katie, when we talk about cancer being preventable, what does that actually mean? And what's an example of cancer prevention that people might already know? [00:02:11] Katie: Yeah. So some cancers are due to chance or just mistakes happening as our cells copy. [00:02:19] Other cancers are because there has been damage to the genetic information within the cell that can be caused by certain things that can cause damage to DNA. So for example, a sort of obvious answer would be skin cancer. Skin cancers can be caused by sunlight, the, the UV light in the sun, and particularly if we burn our skin or, or get sun damage to our skin, increases the chance of us developing a skin cancer. [00:02:44] So you can think of lots of other examples such as cigarette smoking and lung cancer, and so we know that there are a number of different risk factors that increase the chance of our cells developing damage and becoming abnormal cells and growing uncontrollably. So when we talk about prevention, we might think, well, could we reduce some of those risk factors and therefore reduce the chance of those cells getting damaged and becoming cancer cells? [00:03:10] So I gave the example of skin cancer. We might put sun cream on if we're going out in the midday sun, for example. That reduces the damage of the UV light onto our skin cells. Or we might help people to go into a smoking prevention programme or, you know, other risk factors, such as we know that being very overweight can increase the chance of cancer. [00:03:31] We might help people get into more exercise regimes or improve people's diets. So those are the sorts of things that we might do sort of for environmental risk factors. But we also know, particularly in this context, that sometimes people are born, they carry genetic changes within their cells that they're born with, that are inherited, that run through families, and those can also increase the chance of some cancers developing. [00:03:56] And for those people at higher genetic risk, then we might look to other ways that we might reduce that risk. We can't change the genetic changes in their cells, but we might be able to put things in place to reduce the risk for those individuals, and that might be medication, it might be surgery, or there could be other things that we might be able to offer. [00:04:15] Sharon: Yeah, and with that in mind, is there anything more, you know, that you can share about some of those risk factors that someone is more likely to develop cancer? [00:04:25] Katie: Yeah. So actually, the, the biggest risk factor for developing cancer is age. The older we get, the more times our cells have divided, the more chance there is of a copying mistake that, that, that can cause that cell to become abnormal and start growing uncontrollably. [00:04:41] And that's why cancer becomes more common the older we get. We obviously can't change our aging process. Then, as I've said, sometimes we're born with certain specific inherited factors that increase the risk. That might be one big high-risk genetic factor, such as having a cancer gene that's important for, for that process of cell division that isn't working properly. [00:05:04] Or it could be that we have multiple lower genetic risk factors that can kind of add up together to increase the risk. And those often interplay with some of those environmental factors that we've talked about, like smoking, for example, or weight, or alcohol or other things like that. So most cancers are due to aging, and then there's a sort of interplay of genetic factors, but environmental factors as well. [00:05:30] Sharon: That's really interesting to understand. And the focus of this podcast is sort of looking at kind of Lynch syndrome and what findings have come out around aspirin and having a low dose of aspirin. So I want to kind of explore what Lynch syndrome is and, and then bring in Drew to talk about his experience of having Lynch syndrome and how he got involved in the trials themselves. [00:05:49] So from what I understand, Lynch syndrome is a genetic condition that can make some people more likely to have the chances of developing into bowel cancer. And Drew, this is your opportunity to sort of talk about what that's been like living with Lynch syndrome. And, you know, I'd like to understand more about your story and how it came about that you discovered that you had Lynch syndrome, and to share with our listeners your journey. [00:06:13] Drew: Yep. So in my case, I discovered I had the colon cancer before I discovered I was a Lynch syndrome carrier Basically, at the age of 50, I noticed some change in my health. You know, I was becoming a little bit more tired. My bowel movements had changed or whatever. So, I went to the GP and the GP basically said, "Well, you're probably too young for cancer, so let's look at other alternatives." [00:06:37] And I had blood tests and I had low iron, so I was on iron tablets for three months and whatever. Then eventually I went back and finally the GP said, "Well, let's try a colonoscopy." And the colonoscopy revealed that I did actually have colon cancer. And then very quickly I had surgery and, uh, then following that, I kind of asked the question, "Well, why me?" [00:06:59] You know, I'm only 50, 51. Yeah. You know, why me? [00:07:02] Drew: And basically, I was told, "Well, it's probably genetics." And then I was referred to, you know, St George's and Katie and I had the test and discovered that I was actually a Lynch syndrome carrier, and that's why, you know, I'd got the colon cancer at the age of 50, so. [00:07:17] Sharon: I mean, that's quite a journey. I mean, how did you feel when you're already on one pathway and then having to kind of find out more, you know, what was your experiences? What was the impact on your life? How did you, how did you feel? [00:07:27] Drew: I think I was lucky in that I had a very good surgeon. I had surgery very quickly, so that was the first hurdle. [00:07:32] Then I had to go on to chemotherapy, and the chemotherapy obviously is far worse than any surgery or anything else that comes before or after. But having got through that, then I went through the St George's onto the Lynch syndrome system. So, the most important thing then really was to basically identify what that meant for me, but also because it was an inherited characteristic, what it meant for my family. [00:07:57] One thing that was interesting, and I say, you know, the, the GP was saying, "Well, you're too young to have cancer," is that there wasn't any history of cancer in my family, you know, looking at older relatives. So, you know, to be fair to the GP, that wasn't an obvious marker. So basically, yeah, it was let's, you know, find out what it means now going forward. [00:08:21] Sharon: So, can you just take us back to when you were diagnosed with Lynch syndrome? What sort of guidance were you given at the time about managing your cancer risk? [00:08:30] Drew: Well, following the surgery, I was given various statistics which were fairly grim on what your percentage survival rate were in three years, five years, 10 years based on the surgery, whatever. [00:08:39] And that was kind of a bit harrowing. But, you know, assuming I'd get through five years, I felt it was, my chances were quite good. As for myself living with, living with Lynch syndrome, that, you know, I was aware that having had the colon cancer, I then had increased risk of other cancers. So since then, I've been on a screening programme, and I have colonoscopies or gastroscopies every year or two years. [00:09:04] So that's been very good. So, I believe now that if any other cancers were to appear, I would probably know very early on because they would be detected through a screening process before they got to a point where they would be, you know, maybe too difficult to resolve, so. So that's-- I think the screening programme, has been very, very good. [00:09:23] The main issue for me was what it meant for my family, being a genetic thing. So very quickly, my children, who were teenagers at the time, were both tested, and they went through some counselling with Katie beforehand, you know, about what it would mean for them to get a positive or negative result. [00:09:42] Unfortunately, my daughter was tested as negative, but my son was tested as positive, so he's now on the same cancer screening programme, and has colonoscopies every two years. So yeah. The mystery really, though, is where I inherited it from because my father died when I was very young. My mother was in a care home at the time, and I wanted to get her tested. [00:10:07] And at the time, her GP wouldn't test her on the basis that she was unable to give consent. But fortunately, I had power of attorney, and we could persuade him to do the test. But she tested negative. So I'm assuming I inherited it from my father's side. But most of my grandparents on that side of the family lived into their nineties without any apparent cancers. [00:10:32] So it's still a bit of a mystery how I inherited it, but what was important for me was to know which side of the family I'd inherited it from because obviously with cousins and whatever on different sides of the family, I wanted to be able to tell them what the situation was. My brother also tested negative, which was a positive. [00:10:54] So at the moment, it's just my son and I that have the defective gene. [00:10:59] Sharon: I'm sorry to hear that about your son, but does it- [00:11:01] Drew: Well, well, I mean, he, you know, he has to go through a colonoscopy every couple of years, which, you know, obviously is not a pleasant experience. But at least he knows that, you know, the first sign of any problem, the medics will be aware of it, and he'll be able to react. [00:11:16] Sharon: Has it changed your outlook on life, having this window in possibly knowing stuff or not knowing stuff? How has that affected you and, and your son as well? [00:11:25] Drew: I think knowing is always a good thing. And obviously, I wish I'd known earlier, and then, I could have taken more measures earlier on. So, I think knowledge is definitely a good thing. And it would be great if more people could be tested or could find out if they were carriers at an early age, I think. [00:11:42] Sharon: Yeah. That is really important. And moving into about the trial more broadly, scientists have known that there's been a link between cancer and aspirin for some time, with fewer cancers observed in people who take aspirin. So coming to you, John, could you share a bit more about the history of inherited cancer research and how the focus of Lynch Syndrome came about? [00:12:02] Because this isn't new, is it? [00:12:06] John: No, absolutely, Sharon. And in fact, this story, my story in this space begins 40 years ago when I was one of the geneticists who set out to try and find the genes that we've just been talking about. At that time, the group of patients who were the most obvious to begin with were young people with a condition called familial adenomatous polyposis, or FAP for short. [00:12:26] And they'd get thousands of polyps in their bowel, and the only way to treat that was to actually remove the whole bowel when they reached adulthood, which is a fairly extreme intervention. And I was running, I was setting up a registry. We were trying to find the gene at that time, and we'd just found it, in fact, but we also were trying to find all the families. [00:12:44] And I'd taken over responsibility for all the genetic services in the north of England, in the North East and Cumbria. And we'd, I'd started identifying families with FAP, and we went to visit one of those families, and this was the kind of light bulb moment for me because I walked into the room and mum had had her colon removed, and her son, Jonathan, had just had his first colonoscopy at the age of 12, and it was clear. [00:13:07] And I was about to give them the good news, but as I walked in, I noticed that he had little bumps on his forehead called osteomas, little bony bumps. His mother had them just the same, and it was one of the features of this condition. So I knew he had the gene even though he hadn't yet got the polyps. [00:13:21] Sharon: Wow. [00:13:22] John: And it made me think, wouldn't it be nice if we could do something to prevent these things happening rather than just waiting for an operation? And as it happened at the time, I was leading the English end of a big study, which you'll probably be aware of, which we're, we're, we were doing the vitamin study on women with spina bifida babies, and we were just about to identify folic acid as a way of preventing spina bifida in pregnant women. [00:13:45] So I had these two thoughts in my head. Maybe we could set up a trial like this folic acid trial, and then one of my friends in Edinburgh said, 'Have you seen this paper from Melbourne?' Gabriel Kuhn had just done a big study looking at people with colon cancer. It seemed that people who took a lot of aspirin didn't seem to get as much bowel cancer in Melbourne as those who didn't. So that was the design set up. [00:14:08] We were applying to Europe for a concerted action, so we had to think of an acronym that began with CA. So I, I came up with Concerted Action Polyp Prevention. But then in 1993, just as we started that trial, we were involved in finding the first of the genes for Lynch syndrome. We had a big family in Northumberland where there were lots of people like Drew's family, and there were three generations of cancer in the family. [00:14:31] So CaPP2 was immediately born in my head. In 1999, we had our first recruit, and we recruited until 2005. We found, in total, 1,000 people in 16 countries to join in, and we gave them two aspirins a day or two dummy tablets. Two aspirins is quite a big dose, but back in my day when I was a junior doctor, we used to give many more tablets of aspirin to people with arthritis. [00:14:57] So two tablets wasn't such a big deal. Nowadays, it's seen as a very high dose. And it worked. Basically, to cut to the chase, when we looked in 2010, the people who were getting the aspirin were getting less bowel cancers. In fact, it was a 50% reduction. So the people who took two aspirins had half as many bowel cancers and fewer cancers of other types as well. [00:15:19] We realised, although, at this point, immediately we saw that it was working, we knew we'd need to do another trial to see whether a smaller dose of aspirin would be just as effective. So CaPP3 began, and the great news is that what we'll be reporting in the journals in the next few days when it gets published, is that the people who were taking  CaPP3 aspirin in any dose were tracking exactly the same as the 600-milligram group in CaPP2. [00:15:46] So we're pretty sure that it works. We're pretty sure that the small dose is just as good. And the great news was that we had fewer side effects in that group. And so in fact, no one had to go to hospital for a transfusion or anything, you know, like that. Whereas in the 600-milligram group, we had a few people who needed treatment because, as you know, and everyone knows, if you take aspirin, there's a higher chance of having an ulcer that causes a bleed. [00:16:10] And that was always the anxiety. But people like Drew were courageous enough to take the chance because they knew we needed to know the answer to this. And of course, when you compare it to the risk of getting cancer, taking an aspirin is a relatively small risk. [00:16:26] Sharon: So, what were your kind of considerations when you were designing the trial, having that knowledge? [00:16:32] John: Well, the first thing is it has to be fully informed consent, which means that you have to explain to people what that risk is. The important thing about aspirin is that doctors have a much worse opinion of it than it deserves because if you work in a hospital, you'll often see people coming in who've had a bleed. [00:16:48] It's not always caused by the aspirin. The thing is, if you're coming with a bleed and you're on aspirin, everyone blames the aspirin. Right. About half of them would've happened anyway. In fact, the, the irritation of the stomach is much more of a problem in older people So in fact, the average age of the people in CaPP2 and CaPP3 was about 45, 46 when they started. [00:17:08] Drew was a little bit older, but, but people in that sort of middle age group are much, much less likely to get into trouble than people in their 70s and 80s. And it's people also who've had a history of ulcers that have a bigger problem. We also knew that if you had a stomach infection called H. Pylori, which is itself a risk factor for cancer, and about one in six people carry that bug, and we knew that if we fixed that with antibiotics, that would significantly reduce the risk of bleeding as well. [00:17:37] So it was a manageable risk. It was something we could share with people. They knew they were taking a bit of a chance. But actually a good way of putting it in terms of the risk, for people in middle age, the risk of a low dose of aspirin is about the same as the risk of having a colonoscopy, which is very small, but it isn't completely without risk. [00:17:56] Sharon: Yeah, and Drew, kind of like hearing this sort of incredible, like, backstory about how we've got to these trials and where we are today What was your experience like as a kind of participant of this trial? [00:18:08] Drew: I understood I was going to be on 100, 300, or 600, but wouldn't know for at least three years, or was it five years? I can't remember. [00:18:15] And then sometime later in the post we got these packs, and it was ... I remember at the time thinking it was like a rather dull advent calendar - ... in that you'd have the days of the week- ... with the little, with the little windows, and you'd, you'd pop the tablets out three times a day and take them. [00:18:31] So I did that. I think, you know, I, I don't think I ever missed a day or whatever. Initially, I thought I must be on a really low dose, because I didn't actually notice any side effects. You know, I remember saying to my wife, I said, "Oh, I think I must be on the lowest dose, because I don't see any side effects." [00:18:46] It was a surprise years later when I was told actually I'd been taking 600, so. [00:18:51] Sharon: Wow. [00:18:52] Drew: It was quite an easy experience really. [00:18:54] John: We had a lot of problems. We had to pack the aspirin in six-month packs, because it was very expensive to pack this stuff up. It cost... We got the aspirin free from the Bayer company, but it cost us more than a million pounds to actually put it in, in the packs to satisfy the regulations. [00:19:10] Uh, and a lot of people complained that the packs were a bit big and awkward, but that was just, you know, a constraint. But it was not that big a deal once people got into it. But we did get a lot of complaints about the size of the packets, which we couldn't do anything about that. [00:19:24] Drew: They came regularly through the post, and, you know, so every three months or whatever I got another supply, and I just carried on taking them. [00:19:30] Yeah, so. [00:19:31] Sharon: What was going through your mind when you were kind of waiting for this potential outcome, Drew? Because you, like you say, it was, you know, it was a long time taking part. What was... Especially as you were opening your, you know, your package a day, knowing exactly what you were going to get. [00:19:44] Drew: Well, I, I kind of knew it would be a long-term thing. [00:19:47] I think I was committed for five years initially. But I carried on taking the aspirin for another probably five years after that. So yeah, I was just sort of happy to take the aspirin and then sort of wait to see what the results would be. As I say, that I didn't really notice any side effects, so I wasn't really worried that it was having any detrimental effect on me. [00:20:09] So I was curious to see what the, what the results would be. [00:20:12] Sharon: Yeah. John, the trial has provided like the evidence that, you know, low-dose aspirin can prevent bowel cancer. But are there any challenges that still exist with translating this research into clinic and ultimately patient care? [00:20:26] John: Well, yes, and I'm going to hand back to Katie, who's actually leading the charge on, on getting it into practice as well. [00:20:32] But just to say that I, I'm actually now literally on my other computer finalising my bid to go back to Cancer Research UK because we want to go for three more years. Wow. We said that we would follow people for 10 years after they'd finished their ... or after they'd started, so, you know, for at least 10 years. [00:20:50] So the last person to join didn't finish until 2024, so we won't get to that person. It's Robin and one of my patients. We won't get to Robin's 10-year anniversary until 2029. Oh, yeah. By which time, obviously, Drew will be even further on. But that will give us at least 10 years of follow-up because we know that there is this delayed effect, and that was seen right back at the beginning when people looked, for example, the nurses study in America, where they followed 86,000 nurses and just asked them if they took aspirin. [00:21:18] And nothing happened for 10 years, but those who were taking aspirin for more than 10 years saw a benefit. So in the general population, it probably takes that long to kick in. And so we need to keep going for just a while longer. It's not as expensive now because we're not giving people aspirin anymore. [00:21:33] Sharon: Yeah. [00:21:34] John: But one of the reasons we g- we made Drew's dose blind was because we wanted to know what the side effects would be when you didn't know how much you were getting There's a danger if you're getting a higher dose, you're more likely to complain. And actually, it did work out that the people on the lowest dose had the fewest side effects, even slight side effects. [00:21:51] The only thing we can't escape from is if you're taking aspirin, you get bruising more easily because it blocks the platelets, which are the little tiny blood cells which plug up little holes in your blood vessels when they leak. The good news is we now know that platelets turn out to be right, a major factor in triggering cancer. [00:22:09] And so the aspirin, by blocking the platelets, is actually reducing the risk of cancer, but also reducing the risk of cancer spreading in the body. So this is new research, and we've got another big research project in collaboration with a team in Cambridge who are, uh, pursuing this. Also, the other exciting news is that my other partner, Ruth Langley, is running a big trial of people with cancer, and those who are given aspirin as part of their treatment have less likelihood of getting spreading cancer later on. [00:22:39] So the aspirin is clearly doing something good at many levels in the system. Surprisingly, and we think it might be partly, partly because we used to have a lot of salicylate in our diet, which is what aspirin's made from. And we think that maybe we're putting back something that the body actually was used to having. [00:22:57] Yeah. But modern diets don't contain any, any salicylate because of the way we prepare our food. So it may well be that a little bit of aspirin's a good thing for everybody, but obviously, that's a choice that each person will have to make. [00:23:09] Sharon: Yeah. I mean, it's a real powerhouse of a, of a drug essentially, which you're finding out more about its benefits as, uh, as research goes on. [00:23:18] So Katie, can you just give us a bit of a broad overview of Genomics England's new adults program, which is kind of looking at this sort of area of work and, and what, how can it benefit people? [00:23:29] Katie: Yeah. Thank you, Sharon. So, the adults programme at Genomics England is being funded by government, and the government wrote about it in the 10-year NHS Health Plan, the Life Science Sector Plan to run a large-scale genomics population study. [00:23:44] So looking at how we can obtain genetic information from people in the population and look at more proactive and preventative healthcare, and can we generate evidence on where, how, and why the NHS should start applying genomics into kind of more population health measures. So, there's sort of two sides to this. [00:24:05] So the first is thinking about pharmacogenomics, which is basically about how genetic factors influence how we respond to drugs. So lots of people have had experiences of having side effects from drugs, we've just been talking about that with aspirin, or for drugs not working so well for them. And we know that there are certain drugs that genetic factors can influence whether you should take the drug at all, or if you do, what dose you should take, whether it's going to work for you or not, whether you might be more likely to get side effects or adverse reactions. [00:24:34] So part of the programme's looking at that. And then the other half of the programme will be looking at sort of is, are the genetic factors relevant for sort of serious and high-risk conditions in the adult population? So we could take bowel cancer as an example of that, a common condition, breast cancer, you know, common cancers or cardiovascular disease. [00:24:58] We know there are certain genetic factors for some people that have significantly increased their chance of developing those serious adult onset conditions. Can we find those people in the population and then put measures in place to prevent that? So, you know, even just thinking about Drew's story, he didn't have a family history of cancer. [00:25:16] The first time that he knew he had Lynch syndrome, he'd already developed bowel cancer. And we know that many people that have Lynch syndrome or other high-risk cancer genes are unaware of their status in the population, and so, um, the idea of this program is to really look at, well, if we were to, to look for some of these very high-risk genes in the general population, could we then put measures in place to reduce the chance of them developing the serious condition as a consequence? [00:25:44] So instead of Drew presenting with his bowel cancer, we'd actually already picked it up, despite the fact he doesn't have a family history, and we'd offered him, let's say, aspirin if we'd known the information at the time, and we could maybe have prevented him from developing bowel cancer. [00:25:58] So it's really exploring looking at that a little bit more. [00:26:02] Where can we get genetic information in the population? Where might there be a really well-evidenced, like all the work John's done over 40 years, is really well-evidenced now. Yeah. Yeah. Where are there these opportunities for us to turn the dial on some of these common adult onset conditions? [00:26:20] Sharon: What other challenges do you think with getting this out there do you see? [00:26:25] Katie: Uh, I think there's, there's lots of challenges. I think it's a really com- ... complex programme of work. The first thing is that the risks might be different for people in a population than have a family history. So where I've worked for, for years, and John as well in, in clinical genetics, we've seen the highest risk people, the people with lots and lots of cancer in their family because they're the people that are presented to healthcare services. So we've worked out the risks based on that population. It will be really different when we move to the population setting. We'll find fewer people, and the risks might be lower because there might be other factors that are giving them a lower risk. But that's not to say the risk is zero. [00:27:05] It's probably still raised. So then what we need to do is we need to consider, okay, well, what can we do to intervene, taking into account this change of context from people that we found through clinical services to people that we see in the population. And aspirin is a great example of this. [00:27:22] So, you know, if we find that someone has a Lynch syndrome gene, then taking aspirin, unless there's a really good reason for them not to take aspirin, is almost certainly going to be low cost to the NHS and really significantly reduce the chance of them developing bowel cancer with a low risk profile. So where are those opportunities? [00:27:41] And that isn't clear cut, and that's why we need a large scale research programme that can try to help the NHS answer some of those questions, so it can decide how best to spend its money in, in the people that are most likely to benefit from it with the least amount of risk or harm to them. [00:27:58] Sharon: That makes sense. And, and so, you know, going to you, Drew, what are your kind of thoughts on some of the challenges that Katie's highlighted? And is there anything else that you think needs to be improved in better supporting people living with inherited risk of cancer in the future? [00:28:14] Drew: In the brief sort of 10, 15 years or whatever since I've been s- suffering, awareness has increased greatly. [00:28:21] I mean, for example, my GP now knows about Lynch syndrome, whereas I don't think she did when I was first diagnosed, and I think there is a little bit more awareness out there, but I still think it's a lot less than there would be for, say, for breast cancer. So for example, when a high-profile personality reveals they've got breast cancer, you often get information about inherited risks. [00:28:44] You don't seem to get that with colon cancer. You know, when it's announced that so-and-so has died or is whatever, you don't get that same, you know, it, it might be a genetic thing. I mean, when I was first told people that I had bowel cancer, the response I got usually was, "Oh, poor diet, was it?" [00:29:04] And I always felt a bit upset, that, you know, actually my diet was fairly healthy. And that was the assumption that people had. So I think anything that gets the message out there that there is a risk, an inherited risk, I'm not sure what the statistics are now, Katie, is it one in 400 people might be a Lynch syndrome carrier or something like that? [00:29:24] You know, it's relatively high for something that is, if you know in advance you're at risk, you can do something about it. But like me, you know, I waited until it was too late, because I didn't know, and then had to have the surgery, so anything that promotes the message that there is a risk. I know some people don't want to know about their genetic makeup. Obviously, that's a choice. But I think to give people, as many people as possible, the choice must be a good thing. [00:29:54] Sharon: Yeah, absolutely. And I think one thing I've noticed through this thread is the sort of theme of funding and what gets funding and the amount of time it takes to, to kind of get that funding. [00:30:05] Is there anything you wanted to add around the kind of funding model, around why some things get funded, you know, uh, more prominent, like Drew's point, obviously, talks about if someone high profile kind of comes forward and says XYZ, that gets the spotlight shone on it, and there might be research going that direction compared to s- to, to other cancers. [00:30:23] John: So maybe I could speak at that. So partly because of my experience, I've now been made chairman of the grant committee at Cancer Research UK for prevention and population research. And there is a real drive to push more resource into prevention for the obvious reasons. [00:30:39] Katie: Yeah. [00:30:39] John: And also, it's got to be remembered, it's very difficult for the drug companies to fund this because it takes such a long time that the drug's- Mm [00:30:46] out of its patent before they actually get to use it. So, it's very difficult from a business point of view to fund research into prevention. But they are keen to help us, uh, but we really need sort of central government and the charities to focus on prevention if it's going to make a difference. [00:31:02] And just on Drew's point on diet, I mean, diet is still important even if you have Lynch syndrome. In our CaPP2 trial, the people who were overweight were more than double the risk of cancer. So it's not like an either/or. If you've got a higher genetic risk and you have a bad diet, then that's, you know, is going to contribute. [00:31:21] But the other exciting thing is, of course, we now have medical ways of treating obesity in, in people. So, one of the interesting areas is whether we should be, in the same way as we are for other high-risk populations with overweight, we should be giving overweight people with Lynch syndrome, help to lose weight because that will also reduce their risk. [00:31:41] It's also worth just dropping in at the last moment here is that this is also a good news story in terms of treatment and further prevention. We now have a new class of drugs called immune checkpoint inhibitors, which specifically target the types of cancer that Drew had and are much more effective in curing them And also, we've just been given funding to do a project called LynchVax, which I'll be helping with, but it's led by David Church in Oxford. [00:32:05] And this is developing a vaccine against cancers in people with Lynch syndrome. The great news is it'll probably work alongside aspirin because we know the aspirin is enhancing the immune response. So the two together may make this a curable condition. [00:32:18] Sharon: That's actually incredible. I mean, that, it gives so much hope for people. [00:32:23] And I just wanted to find out if you had any more kind of reflections as we close, because we're going to come to the end of our podcast today. If there's anything more that you wanted to share, anything that has been missed, or anything that you want our listeners to know, and I think I'm gonna come to you, Drew, first, because you're the person who's had to sort of live through this and, and go through this journey along the way. [00:32:41] Drew: I think just basically, if you're not sure, get tested. Obviously, there are financial constraints. I'm sure that running a DNA test is quite an expensive business. But I think if you've got any history of bowel cancer in the family, you've got any concerns about your health, speak to a GP and see if you can get tested as quickly as possible. [00:33:00] And then, to get a better message out there that there are risks of inherited colon and other similar cancers, so. [00:33:11] Sharon: Yeah, so it's getting that, messaging out, um, for people to understand more and make those informed choices. And Katie? [00:33:18] Katie: I mean, I would say that the power of, of our, you know, NHS and our academia and, and our healthcare system has been collaboration. [00:33:26] Sharon: Yeah. [00:33:27] Katie: There's so many moving parts. There's commissioners, there's funding, there's the evidence, there's research, there's healthcare implementation. The UK's a really amazing place to work in genomic medicine, and I think that's partly because of the amazing collaborations that we have, and the way that we can translate research into healthcare as John's team have done with this amazing study. [00:33:48] So let's all keep working together, please. [00:33:52] Sharon: Absolutely. And John, it feels like this is your lifetime's work. [00:33:58] John: Well, I've become aspirin man, it wasn't intended. But Katie's done fantastic work in her role as chair of the Cancer Genetics Group in the UK, so we've now implemented a, [00:34:06] we're the first in the world to really make this an absolute directive to the GPs and all, to all doctors to say, "People with Lynch syndrome need to be offered aspirin." And so that's a great step forward. But we also need to get it into the British National Formulary, and I'm working with their team so that the GPs are empowered to do this. [00:34:24] It's actually part of their care package. But I would just say we've still got a long way to go. We've now got a national list of all the people with Lynch syndrome, like Drew, to make sure we offer them all a colonoscopy, but there are only 14,000 people after several years of really pushing. [00:34:40] Sharon: Right. [00:34:40] John: We think in the national population in all ages, it's about 1 in 300. That's a lot of people. That means there's about 150,000 people like Drew in the country, and we've only found 10% of them. So we can't just rely on family history for all the reasons Drew explained. You know, I mean, Drew's dad probably died of Lynch syndrome, but we don't know because we've lost that record. [00:35:02] So now we're checking every bowel cancer to see if it might be caused by Lynch, and that programme is now kicking in, and we're picking up a lot more gene carriers as a result of that. But there's still a long way to go to get co- get people aware of Lynch syndrome, to think of it when someone presents with a cancer, not just of the bowel, but in the womb, in the kidney, in other parts of the body. [00:35:23] It's not just the bowel, but that's the most important group. [00:35:26] Sharon: Yeah. [00:35:26] John: So there's still a long way to go. [00:35:28] Sharon: Where you've come to now is still an incredible achievement, even though we've still got a long way to go, and I don't think we should ever lose sight of that. So we're going to wrap it up there. Thank you to our guests, Katie Snape, Professor Sir John Burn, and Drew Hyde, for joining me today as we discuss cancer prevention. [00:35:48] If you'd like to hear more like this, please subscribe to Behind the Genes on your favourite podcast app, and thank you for listening. I've been your host, Sharon Jones, and Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Dave Howard at Bespoken Media.  

Na 10 jaar neemt Aleid Wolfsen afscheid als voorzitter van de Autoriteit Persoonsgegevens, de privacywaakhond. In een tijd waarin de cyberdreiging groeit, het datalekken regent en AI nieuwe uitdagingen met zich meebrengt, blikt hij terug op de afgelopen jaren.  Sven op 1 is een programma van Omroep WNL. Meer van WNL vind je op onze website en sociale media: ► Website: https://www.wnl.tv  ► Facebook: https://www.facebook.com/omroepwnl  ► Instagram: https://www.instagram.com/omroepwnl ► Twitter: https://www.twitter.com/wnlvandaag ► Steun WNL, word lid: https://www.steunwnl.tv ► Gratis Nieuwsbrief: https://www.wnl.tv/nieuwsbrief   

Elon Musk er historiens første dollarbillionær etter at SpaceX gikk på børs. Mens KI-euforien tar av og flere selskaper skal på børs, advarer økonomikommentator Sindre Heyerdahl mot at veldig mye politisk og økonomisk makt samles på svært få hender. Er det bærekraftig? Foto: Hamad I Mohammed/Reuters.

"It seems many Singaporeans are being asked not to set aside the Full Retirement Sum (FRS) in their RA at age 55. Instead, they are advised to set aside only the Basic Retirement Sum (BRS) - which is half of the FRS - by pledging their property, and to redirect the other half into an ILP'", wrote Christopher Tan, CEO of Providend, in a recent article in the Business Times. Michelle Martin unpacks the trade-offs between certainty and growth when taking such advice. Chris explains why projected returns can sometimes create a false sense of security and the risks retirees face if they follow such recommendations and markets fall early in retirement. Discover how CPF LIFE fits into a retirement portfolio and what questions investors should ask before making long-term decisions.See omnystudio.com/listener for privacy information.

Oranje is neergestreken in de Verenigde Staten en het WK staat voor de deur, maar ondertussen barst de transfermarkt los. Dumfries maakt de droomstap naar Real Madrid, PSV wil recordbedrag voor Saibari die in de serieuze belangstelling staat van Bayern München én Theo Janssen onthult wie Ajax allemaal heeft aangeboden op Transferroom. Ook vraagt Brighton de hoofdprijs voor Van Hecke en is er nog meer nieuws uit binnen- en buitenland. Dat en meer in de nieuwste aflevering van #DoneDeal!Speel de WK-topscorers Quiz: de top vijf topscorers van de laatste zes WK's: https://www.voetbalprimeur.nl/nieuws/2097209/de-wk-topscorers-quiz-de-top-vijf-topscorers-van-de-afgelopen-zes-wk-s.htmlSee omnystudio.com/listener for privacy information.

I ugens Radio Information analyserer vi de historisk lange regeringsforhandlinger, der nu omsider synes at nærme sig en afslutning. Vi diskuterer Tysklands kontroversielle EU-forslag til Ukraine om et 'halvt' medlemskab. Og så diskuterer vi kritikken af kvindesynet i seriesuccesen 'Euphoria'. --- Da Lars Løkke Rasmussen på valgaftenen ankom til Moderaternes valgfest, blev han tiljublet med et hujende kampråb: »Midten, midten, midten. Lars, han går til den.« Men nu tyder meget på, at Lars Løkke alligevel ikke går til midten, men i stedet går til venstre i en S-SF-M-R-regering med Enhedslisten og Alternativet som støttepartier. Og det efterlader ham med et forklaringsproblem. For hvorfor har Moderaterne valgt en regering, der er afhængig af den »yderste venstrefløj«, som de ellers advarede imod? Og hvorfor gik de ikke til blå blok, som lagde op til en mere liberal økonomisk politik? Natalie Barrington Rosendahl og Laura Friis Wang analyserer situationen og de alenlange regeringsforhandlinger, som nu omsider synes at nærme sig en afslutning. Kan man være lidt medlem af EU? Det er et af de store spørgsmål i europæisk politik netop nu. Tysklands kansler Friedrich Merz har foreslået at udsætte et fuldt medlemskab til Ukraine og i stedet give landet status som 'associeret medlem'. Det indebærer sikkerhedsgarantier og en plads ved bordet – men ingen stemmeret. Ideen har vakt vrede i Kyiv, som frygter at blive holdt hen med et EU-medlemskab light. Er Tysklands forslag en gratis omgang, der har til hensigt at parkere Ukraine i venteværelset – eller snarere en reel, pragmatisk løsning for et land i krig? Tysklandskorrespondent Nina Branner udlægger teksten. På mandag har sidste afsnit af HBO's på én gang meget populære og meget kontroversielle tv-serie Euphoria premiere. The Guardian har kaldt den for »manosfærens våde drøm«, og Politiken mener, at serien i sin tredje og sidste sæson rammer »den absolutte bund med sin utilsløret nydelsesfulde svælgen i seksualiseret nedværdigelse af kvinder«. Bodil Skovgaard Nielsen forklarer, hvad det er ved Euphoria, der – mere end andre kulturprodukter – kan sætte sindene i kog.

These are just the best weekend snack that everyone loves. They originate from Lebanon where they're called ‘arayes'. Eat them as a snack or with salad for a full meal. Makes 12 Ingredients 500g lamb mince 1 onion, grated 2 cloves garlic, grated 3 tsps each ground cumin, coriander, paprika ¼–½ tsp cayenne (optional) Small bunch of parsley, chopped ½ tsp sea salt 6 mini pita breads Olive oil for brushing Dipping sauce ½ cup plain yoghurt 2 tsp pomegranate molasses 2 tsps sesame seeds Method In a bowl mix the mince with onion, garlic, spices, parsley, and salt. Halve each pita bread and tease the layers apart (slightly warm the breads if needed). Take a tablespoon of the spiced meat and spread it into a thin layer inside each pita. Make sure it gets right to the edges. Press flat and brush each pita with olive oil. Heat a pan to medium and fry each filled pita bread until golden and meat filling is cooked. It doesn't take long as it's a very thin layer of meat. Mix all dipping sauce ingredients together. Serve warm pita with dipping sauce. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Adriaan en Simon spreken over: cardio voor het hart / paradijsvogels / Koos, de witte Papoea / slechtpassende peniskokers / de oranje loper bij Van Roosmalen en Groenteman / DWDD / boek en strip over dementie / een stukje levenseinde / Incogni / de stilte van Amsterdam / crowdfunding voor De rat van Arras / Jetten in korte broek / post & post Schrijvers van dienst: Koos Knol / Birago Diop / Wim van Dijk / Annegreet van Bergen / Ludi Boeken / Ger Verrips CROWDFUNDING DE RAT VAN ARRAS https://www.voordekunst.nl/projecten/21253-adriaan-van-dis-de-rat-van-arras ADVERTENTIE Bescherm je persoonlijke gegevens, ga naar incogni.com/VDO en ontvang 60% korting over het eerste jaar, met een 30 dagen niet-goed-geld-terug-garantie. Ook adverteren in Van Dis Ongefilterd? Stuur een mail naar jeroen@steamtree.nl Boeken uit de aflevering bestellen? Dat kan via onderstaande links: Koos Knol – Papoea Blues Koos Knol – Ik droomde dat je kwam Étienne Davodeau – Waar je ook gaat Wim van Dijk - Liefde in tijden van Alzheimer Annegreet van Bergen - Over liefde, Ludi Boeken - Le silence d'Amsterdam Volg het Instagram-account van de podcast: @vandis.ongefilterd Wil je een vraag stellen of reageren? Mail het aan: vandis@atlascontact.nl Van Dis Ongefilterd wordt gemaakt door Adriaan van Dis, Simon Dikker Hupkes en Bart Jeroen Kiers. Bedankt voor uw recensie. © 2026 Atlas Contact | Adriaan van Dis | Simon Dikker Hupkes | Bart Jeroen KiersSee omnystudio.com/listener for privacy information.

De tweede halve finale van de Champions League werd een compleet ander duel dan Paris Saint-Germain - Bayern München. Atlético Madrid en Arsenal speelden met 1-1 gelijk in de heenwedstrijd in het Metropolitano. Een wedstrijd in een ander tempo en met andere intenties. Etienne Verhoeff en Maarten Wijffels bespreken het duel in de AD Voetbalpodcast. Daarnaast komen ook nog een paar punten uit de kraker in Parijs aan de orde. Bart Eulen wordt gebeld over de belangrijke vrijdag voor Vitesse. Beluister de hele AD Voetbalpodcast nu via AD.nl, de AD App of jouw favoriete podcastplatform. Bestel het boek De vraag van Vandaag hier: https://webwinkel.ad.nl/product/de-vraag-van-vandaagSupport the show: https://krant.nl/See omnystudio.com/listener for privacy information.

Kan man tillade sig at optræde i et land, hvor præsidenten truer Danmark som nation? Det spørgsmål blev omdrejningspunktet, da DR Big Band for nylig tog på en længe ventet turné i USA. Timingen kunne ikke have været værre, og kritiske røster fra det hjemlige jazzmiljø, og en bramfri amerikansk sangerinde, fik kun gjort det endnu sværere at jazze i USA uden politiske svinkeærinder. Gæst: Jeppe Bentzen, journalist på Berlingske. Vært: Julie Lindhardt Høimark. See omnystudio.com/listener for privacy information.

Halve beurtjes van Mathieu van der Poel waren niet genoeg om Tadej Pogacar te stoppen in de Ronde van Vlaanderen, waar Demi Vollering de vrouweneditie met overmacht won. Had Van der Poel het anders moeten aanpakken tegen de wereldkampioen? En zo ja, hoe dan? Niek Goedvolk bespreekt het in een nieuwe aflevering van In Het Wiel met Roxane Knetemann en Marijn Abbenhuijs. Want wat was er bijvoorbeeld gebeurd als mannen uit de achtergrond zoals Remco Evenepoel en Wout van Aert wél waren teruggekeerd? Bij de vrouwen won Vollering op haast dezelfde wijze als Pogacar. Het rijden van haar team FDJ-Suez deed ook denken aan de manier waarop UAE bij de mannen koerst. Die luxe had ze andere jaren niet en dus is het niet gek dat het haar nu tijdens haar zesde poging wél lukt om de Ronde van Vlaanderen te winnen. En wat zit er allemaal achter het zegegebaar van de Europees kampioen? Je hoort het in een nieuwe podcast.See omnystudio.com/listener for privacy information.

Today's headlines include: Prime Minister Anthony Albanese has announced the Government will halve the fuel excise for the next three months, in a bid to bring down petrol prices. Victoria Police have shot and killed Dezi Freeman, the man who killed two police officers in the state’s north-east last August. The Israeli military has suspended a group of soldiers who allegedly attacked CNN journalists in the occupied West Bank. And today's good news: Australian researchers are teaming up with international scientists to restore coral reefs around the world. Hosts: Emma Gillespie and Lucy TassellProducer: Rosa Bowden Want to support The Daily Aus? That's so kind! The best way to do that is to click ‘follow’ on Spotify or Apple and to leave us a five-star review. We would be so grateful. The Daily Aus is a media company focused on delivering accessible and digestible news to young people. We are completely independent. Want more from TDA?Subscribe to The Daily Aus newsletterSubscribe to The Daily Aus’ YouTube Channel Have feedback for us?We’re always looking for new ways to improve what we do. If you’ve got feedback, we’re all ears. Tell us here.See omnystudio.com/listener for privacy information.See omnystudio.com/listener for privacy information.

In this edition of BizNews Daybreak, Alec Hogg explores the DA's radical proposal to cut the fuel levy by 50%. Finance spokesperson Dr. Mark Burke details how to cover the resulting R6.5 billion shortfall without raising taxes or increasing debt. Plus, we cover the surprising developments surrounding the Craig Warriner saga, unrest over the proposed lifetime presidency in Zimbabwe, and Wall Street's unexpected resilience.

Waardeer je onze video's? Steun dan Café Weltschmerz, het podium voor het vrije woord: https://www.cafeweltschmerz.nl/doneren/Binnen de academische wereld bestond de neiging om het geweld van Vikingen te bagatelliseren, alsof ze vooral slechte recensies kregen van hen vijandige christenen. Oud Hoogleraar in oud-Germaanse talen Tom Shippey laat daar niets van heel, op basis van de oude 'saga's' van de Noormannen: Vikingar is een werkwoord, piraterij, ze waren knotsgek, hun mentaliteit van ware doodsverachting deed ze in korte tijd andere volken overwinnen die ook bepaald geen watjes waren.Boek van de week: Tom Shippey (2018), Laughing Shall I Die, Lives and Deaths of the Great Vikings, Reaktion BooksJan de Vries, EddaHoofdstuk 3 ‘de strijd om het bestaan' in Liever dood dan Slaafhttps://lieverdooddanslaaf.com/index.php/store/Het-Boek-LIEVER-DOOD-DAN-SLAAF-door-Rypke-Zeilmaker-GRATIS-VERZENDEN-BINNEN-NEDERLAND-p404128655---Deze video is geproduceerd door Café Weltschmerz. Café Weltschmerz gelooft in de kracht van het gesprek en zendt interviews uit over actuele maatschappelijke thema's. Wij bieden een hoogwaardig alternatief voor de mainstream media. Café Weltschmerz is onafhankelijk en niet verbonden aan politieke, religieuze of commerciële partijen.Wil je meer video's bekijken en op de hoogte blijven via onze nieuwsbrief? Ga dan naar: https://www.cafeweltschmerz.nl/videos/Wil je op de hoogte worden gebracht van onze nieuwe video's? Klik dan op deze link: https://bit.ly/3XweTO0

Is the price of beer too much to bear? The Brewers Guild and Hospitality New Zealand reckons so; they're calling on the government to halve the tax on draught beer to encourage people back into pubs and keep struggling businesses going. Breweries say they're under pressure from rising production, and compliance costs and excise tax is adding to the burden. Brian Watson, Chair of the Brewers Guild, and owner of Good George Brewing spoke to Lisa Owen.

In deze VI ZSM bespreekt clubwatcher Tim Reedijk uitgebreid de wedstrijd van PSV tegen Heracles Almelo terug met presentator Kalum van Oudheusden. Verder ook aandacht voor Liverpool, dat weer wist te winnen én Lamine Yamal, die de ster van de avond was in Barcelona.See omnystudio.com/listener for privacy information.

Flying is one of the biggest carbon criminals on the planet, so by flying more efficiently and scrapping business class, will this make fly better for the environment? One person who thinks so is Milan Klöwer NERC Independent Research Fellow at University of Oxford.

Can you help me make more podcasts? Consider supporting me on Patreon as the service is 100% funded by you: https://EVne.ws/patreon You can read all the latest news on the blog here: https://EVne.ws/blog Subscribe for free and listen to the podcast on audio platforms:➤ Apple: https://EVne.ws/apple➤ YouTube Music: https://EVne.ws/youtubemusic➤ Spotify: https://EVne.ws/spotify➤ TuneIn: https://EVne.ws/tunein➤ iHeart: https://EVne.ws/iheart GERMAN PLUG-IN SHARE HITS 30% IN 2025 https://evne.ws/4aXFlr1 SWEDEN PLUGINS RISE AS THE MARKET SHRINKS https://evne.ws/4tKdDoW UK PLUG-IN SHARE HITS 34.6% IN 2025 https://evne.ws/4cAHw4Y TESLA'S EUROPEAN JANUARY SALES HALVE IN TWO YEARS https://evne.ws/46bCUP4 GENESIS ENTERS FRANCE WITH EV-ONLY RANGE https://evne.ws/4rSJyC0 AMAZON'S RIVIAN VAN FLEET TOPS 30,000 https://evne.ws/3ZKmo4L DHL OPENS EV LOGISTICS HUB IN SLOVAKIA https://evne.ws/4tJTzmQ RIVIAN SETS R2 PRODUCTION FOR Q2 2026 https://evne.ws/3MyDO1q STELLANTIS BRINGS DIESEL BACK ACROSS EUROPE https://evne.ws/4qMloIx SUZUKI LOCKS IN E VITARA SPECS FOR AUSTRALIA https://evne.ws/4riLIei VOLKSWAGEN ORDERED TO FACE FRENCH CRIMINAL TRIAL https://evne.ws/4kRHRCz

Marciano Vink, Robert Maaskant, Thomas Verheydt, Gerald Sibon en Bram Nuytinck zijn te gast bij Milan van Dongen en Yordi Yamali in een speciale uitzending van De Voetbalkantine. Er wordt door N.E.C.-verdediger Nuytinck geloot voor de halve finales van de Eurojackpot KNVB Beker. Ook bellen we met matchwinner Jeff Hardeveld van Telstar, die zijn ploeg naar een historische halve finale schoot tegen Go Ahead Eagles. Learn more about your ad choices. Visit podcastchoices.com/adchoices

There's a chill in the air on this midwinter day — and a warm, mouth-watering aroma wafting from the kitchen. That's right: the Lutheran Ladies are brewing up savory pots of soup in an all-new Iron Ladle Challenge! Erin leads off with a Finnish salmon soup (lohikeitto) that leaves her co-hosts drooling. Rachel then shares a trio of seasonally appropriate soups: seafood chowder for holiday decadence, “feel-better soup” for post-holiday recovery, and curried butternut soup (AKA sunshine soup) for midwinter malaise. Finally, Sarah shares her foolproof formula for improving the perfect, healthful (Instant Pot) soup every time. Finnish Salmon Soup (Lohikeitto) (From Erin) Serves 4-6 Ingredients: 1# salmon fillet 2T butter 1 large leek, sliced .25# mushrooms, thinly sliced 8 cups chicken stock or bone broth, divided 1 jar clam juice .5# russet potatoes, peeled and diced 1 lg carrot, sliced 1t whole allspice Fish sauce for salt .5# bag frozen kale (or 1 large bunch of fresh kale) (spinach is too delicate) 10g fresh dill, finely chopped, divided 4-8 tablespoons heavy cream Instructions: Heat 4 cups of stock and gently poach the salmon fillets until just cooked. Remove the salmon to a plate and reserve the salmon broth. When fillets are cool cool, remove and discard the skin. Meanwhile, melt butter in a soup pot and saute the leeks and mushrooms for ~10 minutes. Add all of the stock (4 c from salmon and 4 c remaining) to the pan with the leeks and mushrooms, along with the potatoes, carrots, allspice, and half of the fresh dill. Cook for 10 minutes, or until the potatoes are just tender. Add the kale and return to a simmer. Stir in a couple of dashes of fish sauce for salt (less than 1 teaspoon). Add the salmon pieces to the soup and gently heat until warmed through, just a few minutes.  Add cream, the remaining dill, and salt and pepper to taste. If Freezing (you will use less stock initially) Heat 4 c stock and gently poach the salmon fillets until just cooked. Remove the salmon to a plate and reserve the salmon broth. When fillets are cool cool, remove and discard the skin. Meanwhile, melt butter in a soup pot and saute the leeks and mushrooms for ~10 minutes. Add the 4 c salmon broth to the pot with the leeks and mushrooms, along with the potatoes, carrots, and allspice. Cook for 10 minutes, or until the potatoes are just tender. Add a couple of dashes of fish sauce (less than 1 teaspoon). Strain the vegetables, reserving broth until cool. Divide among 4 freezer containers: Poached salmon Frozen kale and dill. 2oz clam juice/container Vegetables (kale, mushrooms, potatoes, carrots Broth (start with ¾ cup, and distribute the remaining) To serve, heat on the stove until hot, adding a 1 cup container of bone broth to fill out the rest of the broth. While soup is reheating, put a small puddle of cream (1-2 tablespoons) in soup bowl and slowly add hot soup. Seafood Chowder (From Rachel) HT Cari Haan Saute together over medium heat for approx 5 minutes: 1 stick of butter 1/2 onion - diced 1 tsp garlic salt or powder 1/2 tsp thyme Mix in: 1/2 cup flour 1 cup half 'n' half 2 cups milk 4 oz (half block) of cream cheese (softened in microwave) 1 can cream of potato soup 1/2 tsp black pepper 8 oz. can of minced clams (with juice) 8 oz can of tiny shrimp (with juice) 16 oz of flaked crab broken up in desired sized pieces (I use the artificial crab meat) 16 oz of frozen salad-sized (extra small) shrimp (May add milk as needed for desired consistency . . . will need to do this when heating leftovers) Heat until hot throughout. Serve with oyster crackers and shredded Cheddar cheese. Note: May substitute or add additional seafood as desired. The more you put in, the tastier it gets. :) Rachel's Feel Better Soup Note: quantities are approximate. I rarely measure anything for this recipe. Saute in 2 T olive oil: 1 lb. diced chicken 1 c diced celery 1 c diced carrots Cook until chicken is browned and vegetables are beginning to soften. Add 2-4 cups chopped cabbage and/or kale. Cook lightly. Add 4-6 cups chicken broth or an equivalent combo of bullion and water. Add salt, thyme, and turmeric to taste. Add starch of your choice: barley, rice, or noodles. Cook through. Serve with warm tortillas or crusty bread. Curried Butternut Squash Soup (From Rachel) Halve, remove seeds, and oven roast one butternut squash, upside down in a little water. (350 oven for about an hour or until soft throughout) Cool slightly, then use a tablespoon to remove squash from peels Use blender, immersion blender, or foley mill to puree squash In saucepan, combine squash puree with chicken broth (approx. 2 cups), 1 can unsweetened coconut milk, and 1-2 cubes of Golden Curry flavor. Cook over medium heat until all ingredients are blended and soup is hot. Do not boil. Non-curry option: Use whole milk instead of coconut milk, and flavor with salt, pepper, onion powder, garlic powder, or other favorite seasoning. Sarah's Instant Pot Soup Formula Single serving 4(ish)oz meat (beef, chicken, salmon, etc) 8oz baby carrots 4oz green beans or peas (or other legume) 50g cabbage (or a handful lol) 2oz butternut squash 1 Tbs olive oil 1 cup water 2 tsp Celtic gray salt (or to taste) black pepper Brown meat (not necessary with fish) in olive oil. Place all ingredients in Instant Pot. Steam for 0 minutes (will vary by IP make/model) Instant pressure release. Connect with the Lutheran Ladies on social media in The Lutheran Ladies' Lounge Facebook discussion group (facebook.com/groups/LutheranLadiesLounge) and on Instagram @lutheranladieslounge. Follow Sarah (@hymnnerd), Rachel (@rachbomberger), and Erin (@erinaltered) on Instagram! Sign up for the Lutheran Ladies' Lounge monthly e-newsletter here, and email the Ladies at lutheranladies@kfuo.org.

Research conducted by insurance company Royal London Ireland has found that quitting smoking – and vaping – can reduce the cost of your life insurance by half.Ireland has seen a rise in e-cigarette use, with 8% of the population now using them daily in comparison to just 3% in 2016. However, there are concerns that many people don't realise they're considered a smoker when using e-cigarettes and thus don't include it when applying for insurance.Charlie Weston, Personal Finance Editor with the Irish Independent, speaks to Matt on The Last Word.Hit the ‘Play' button on this page to hear the piece.

Today, I'm joined once again by the incredible Dr. Bill Lawrence, a true pioneer in the field of longevity research and one of the most requested guests on this podcast. Dr. Lawrence trained directly with Professor Vladimir Khavinson—the scientist who discovered and developed bioregulator peptides—and has spent the last eight years leading some of the most exciting field research in this space.   Episode Timestamps: Welcome and introduction to Longevity Podcast ... 00:00:00 Origins and early use of bioregulator peptides in Soviet research ... 00:05:39 Organ-specific peptide mechanisms and targeting ... 00:08:28 Dr. Lawrence's collaboration with Professor Cavinson ... 00:12:17 Overview of American clinical studies and study protocols ... 00:14:13 Measuring biological age: telomeres and epigenetic markers ... 00:15:06 Key Russian studies and impact of peptides on mortality ... 00:17:00 Peptides as ultimate epigenetic switches and DNA repair ... 00:20:00 Importance of pineal and thymus peptides in protocols ... 00:22:28 Advances in peptide testing and lab beta-testing ... 00:28:05 Clinical outcomes: organ regeneration and normalized function ...00:35:54 Bioregulator peptides vs. synthetics: modulation vs. boosting ... 00:39:28 Dr. Lawrence's personal telomere and epigenetic age results ... 01:07:56 Impact of stress and meditation on telomere length ... 01:10:37 Group results: significant telomere and epigenetic age reversal ... 01:13:03 System-level organ age tracking and protocol targeting ... 01:27:14 International expansion and next steps in peptide research ... 01:37:03   Our Amazing Sponsors:   Kineon - near-infrared light helps improve circulation, oxygen delivery, and mitochondrial function, which can support focus, recovery, and even overall brain health. Visit kineon.io/NATNIDDAM and get 10% off!   BEAM Minerals - Mineral deficiency support. One shot in the morning, tastes like water, and you've just restored every essential mineral your cells are craving. Go to beamminerals.com, use code NAT20, and get 20% off your first order.   Nootropept by LVLUP - an advanced cognitive enhancement formula that combines fast-acting neuropeptides, cholinergic support, and mitochondrial-boosting compounds to sharpen mental clarity, memory, and long-term brain performance. Visit https://lvluphealth.com/ and use code NAT at checkout for 20% off.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Waarin we zien hoe de Britse Queen Victoria aan het hoofd kwam te staan van een wereldrijk én hoe koloniale onderdanen zich met wisselend succes tegen de Europese heerschappij verzetten.WIJ ZIJN: Jonas Goossenaerts (inhoud en vertelstem), Filip Vekemans (montage), Benjamin Goyvaerts (inhoud) en Laurent Poschet (inhoud). MET BIJDRAGEN VAN: Annelies Gilbos, Pieter Jan De Paepe, Anouck Luyten (jonge Victoria) en Marjan De Schutter (Victoria op leeftijd). WIL JE ONS EEN FOOI GEVEN? Fooienpod - Al schenkt u tien cent of tien euro, het duurt tien seconden met een handige QR-code. WIL JE ADVERTEREN IN DEZE PODCAST? Neem dan contact op met adverteren@dagennacht.nl MEER WETEN? Onze geraadpleegde en geciteerde bronnen:Boeken: Adu Boahen, A. (1987). African perspectives on colonialism. Johns Hopkins University Press. Baltimore.Benson, A.C., Strachey, L. (Eds.). (2018). The letters of Queen Victoria. John Murray. Londen.Evans, R. J. (2023). De eeuw van de macht: Europa 1815–1914. Spectrum. Amsterdam.Grataloup, C. (2024). Atlas van de wereldgeschiedenis. Nieuw Amsterdam. Amsterdam.Maalouf, A. (2021). Een doolhof vol verdwaalden. Ambo|Anthos. Amsterdam.Websites:Crowning the Colonizer. https://museumofbritishcolonialism.org/2023-4-22-monarchy-and-empire-victoria/ (geraadpleegd op 14/11/2025).Perspectives of the Sepoy Rebellion Perspectives Packet. https://larrymcelhiney.com/Sepoy/Sepoy_Rebellion_Perspectives.pdf (geraadpleegd op 14/11/2025).Beeld: Wikimedia CommonsAnno 117 Pax Romana: Geef vorm aan het Romeinse Rijk in deze baanbrekende, strategische bouwgame. Bouw steden en breid je invloed uit over de Romeinse provincies. Download hem nu via annogame.com/herbeginners en bestuur met economische bekwaamheid, diplomatieke vaardigheden of militaire macht. See omnystudio.com/listener for privacy information.

Yellow Brick Road's Martin Bosley joins Jesse to share his avocado and prawn Sandwich with tahini ginger dressing. He says it's a well-mannered and truly pretty sandwich, all subtle pinks and greens. This could also be the perfect salad for a summer lunch. Avocado and Prawn Sandwich with Tahini Ginger Dressing Dressing 1 tbsp Tahini paste 2 tbsp soy sauce 2 tbsp rice vinegar 2 tbsp sugar 4 garlic cloves, finely chopped 2 tbsp ginger, peeled and grated 2 tbsp sesame oil For the sandwich 12-16 large prawns, depending on their size, cooked, peeled and heads removed 4 slices of baguette or crusty bread olive oil 2 avocados 1 tsp chives, chopped 1 tbsp mayonnaise 1/4 Iceberg lettuce, finely shredded 1 tbsp Japanese Shichimi Togarishi spice mix (optional) To make the dressing: Mix the Tahini paste and soy sauce together. Add the vinegar and sugar, stirring until it has dissolved. Whisk in the garlic, ginger and sesame oil. Mix with a little water until it is thin enough to pour over the prawns. Cut the prawns in half lengthways and lift out the black vein that runs along their backs with the tip of a sharp knife. Drizzle the slices of bread with olive oil and grill until one side is golden. Halve the avocado, remove the stone, peel and place the flesh into a mixing bowl. Using a fork gently mash in the chives and mayonnaise. Spread onto the bread, top with the shredded lettuce and the prawn halves. Spoon a little of the dressing over the prawns and sprinkle with the togarishi. *Shichimi Togarishi is made with 7 different spices, including chilli flakes, orange peel, sesame seeds and seasweed. It can be quite spicy, depending on the brand.

A round-up of the main headlines in Sweden on September 4th, 2025. You can hear more reports on our homepage www.radiosweden.se, or in the app Sveriges Radio. Presenter/producer: Sujay Dutt

Na een stralende dag in Zandvoort maken verslaggever Erik van Haren en voormalig coureur Christijan Albers de balans op in een nieuwe aflevering van de Formule 1-podcast van De Telegraaf. De kwalificatie, met pole position voor Oscar Piastri en een derde tijd voor Max Verstappen, wordt uitgebreid besproken. En wat zijn de verwachtingen voor de race op zondag? Ook is er een McLaren-pet te winnen, gesigneerd door zowel Piastri als Lando Norris.See omnystudio.com/listener for privacy information.

Tim Harford investigates some of the numbers in the news and in life. This week:Is the secret to halving obesity rates really just a matter of cutting back on one fizzy drink a day?How many new babies in the City of London have a foreign-born parent? And since fewer than one baby a week is actually born in the City of London, how much should we care?Electricity in the UK is more expensive than almost anywhere else. Why? And is it anything to do with wind turbines?And we help out rival Radio 4 programme Start the Week with a claim about churches.If you've seen a number in the news you think we should take a look at, email the team: moreorless@bbc.co.ukMore or Less is produced in partnership with the Open University.Presenter: Tim Harford Reporter: Lizzy McNeill Producer: Nicholas Barrett and Nathan Gower Series producer: Tom Colls Production co-ordinator: Brenda Brown Sound Mix: James Beard Editor: Richard VadonShow less

P.M. Edition for June 10. A new report out from the World Bank says that the U.S. economy this year will slow to half of its 2024 growth rate, with global economic growth slowing more modestly. WSJ economics editor Paul Hannon talks about the drivers of the slowdown, and how it may change. Plus, as markets reeled in the days after President Trump announced his “Liberation Day” tariffs, lawmakers and their families traded stocks heavily, according to a WSJ analysis. We hear from Katy Stech Ferek, who covers Congress for the Journal, about how the rules around trades like these could change in the future. And we exclusively report that U.S. government agencies tracked Elon Musk's foreign visitors in 2022 and 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices